IE
KRBP

Israel Englander’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Israel Englander’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,053
Closed -$13K – 7717
2022
Q2 		$13K Buy
+1,053
New +$16.6K ﹤0.01% 6614

Other funds holding KRBP

ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $448M AUM 50.36% 1-Year Est. Return

Israel Englander's KRBP Position: Q3 2022 in Review

Israel Englander sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q3 2022, closing a stake of 1,053 shares — an estimated $13K sold.

Israel Englander first reported a position in KRBP in Q2 2022 and held it in 1 quarter. The position peaked at $13K in Q2 2022. 16 funds tracked by Wall St. Rank hold KRBP as of Q3 2022.

  • Israel Englander reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Israel Englander sold 1,053 Kiromic BioPharma, Inc. Common Stock shares in Q3 2022, an estimated $13K.
  • Israel Englander first reported a position in Kiromic BioPharma, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Israel Englander's Kiromic BioPharma, Inc. Common Stock position peaked at $13K in Q2 2022.
  • 16 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q3 2022.

Based on Millennium Management's 13F filing for Q3 2022, filed 14 Nov 2022.